Citi downgraded Krystal Biotech to Neutral from Buy with a price target of $204, up from $195. The firm said that Vyjuvek had a “solid quarter,” thought the key debate on the launch is sustainability of Vyjuvek revenues. With Krystal’s net cash of about $630M, the firm’s disicounted cash flow implies $204 per share, and the effective tax rate of about 13% implies a revised Neutral/High Risk view, the analyst tells investors in a research note.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on KRYS:
- Krystal Biotech Announces Second Quarter 2024 Financial Results and Provides Business Updates
- Is KRYS a Buy, Before Earnings?
- Krystal Biotech to Report Second Quarter 2024 Financial Results on August 5, 2024
- Krystal Biotech participates in a conference call with Cantor Fitzgerald
- Krystal Biotech, Virtu, StepStone, Cactus Inc., Tidewater to join S&P 600